Smart PSA boosted targeted screening and found more aggressive prostate cancers in Black men in Chicago trials.
Patients with advanced prostate cancer may need periodic imaging scans to catch tumor growth even with stable levels of ...
A large analysis suggests that a multivariable risk assessment tool, called Stockholm3, can detect substantially more ...
Phase 3 data suggest PSMA-PET-CT could reduce unnecessary prostate biopsies in selected high-risk men, though longer ...
A 74-year-old man with an active lifestyle and no family history of prostate cancer presented with mild urinary hesitancy and ...
The expanded indication makes risankizumab the first IL-23 inhibitor available for pediatric patients weighing under 40kg with plaque psoriasis or psoriatic arthritis, supported by phase 3 OptIMMize ...
The interleukin 23 inhibitor was approved for treating moderate-to-severe plaque psoriasis in adults in 2019 and for active ...
Indications now include pediatric plaque psoriasis and active PsA starting at age 6, positioning risankizumab as the first US-approved IL-23(p19) inhibitor for <40 kg pediatric patients. Weight-tiered ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results